All eligible patients will receive Endostar in combination with Gemcitabine plus Platinum-based chemotherapy for 4 cycles (21 days for each cycle). Endostar treatment will continue after completion of chemotherapy cycles until disease progression. Efficacy will be evaluated every two cycles.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histological or cytological diagnosis of inoperable stage IIIB/IV NSCLC
At least one measurable lesion
Age of 18-75 years
Life expectancy \> 3 months
ECOG performance status 0-2
Adequate hematologic, renal, and hepatic function
You may not be if
Prior systemic chemotherapy for NSCLC
Evidence of any unstable diseases (serious infection, grade 4 hypertension, unstable angina, congestive heart-failure, compromised renal or hepatic function, nonhealing wound or bone fracture)
Concurrent anticoagulation therapy
Evidence of bleeding diathesis or coagulopathy
Pregnant or lactating women
Allergic to E.coli preparation
Clareo Health | A Study of Endostar Combined With Chemotherapy Followed by Endostar Maintenance Therapy to Treat Advanced Non-small Cell Lung Cancer (NSCLC)
